跳至主要内容
临床试验/NCT02882815
NCT02882815已完成不适用

Post Market Clinical Follow-up Study of IrisFITTM PFO (Patent Foramen Ovale)

Lifetech Scientific (Shenzhen) Co., Ltd.3 个研究点 分布在 2 个国家目标入组 85 人开始时间: 2014年9月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
85
试验地点
3
主要终点
Device related adverse event up to 12 month follow-up

研究概览

简要总结

The purpose of the study is to collect more data about performance and safety of the device called "IrisFITTM PFO occluder". This data will be used to help more patients who will accept treatment with this device in the future.

Patients will undergo routine examination, procedure and follow-up. Related data will be collected and kept in a way that patient info is well protected.

详细描述

This is a Post Market Clinical Follow-up study. Informed consent will be obtained from the patient or from a legally authorized representative of the patient at screening. The patients will be screened (pre-procedure) to determine eligibility for the study. At screening, patients will be assessed for study eligibility by the inclusion/exclusion criteria through their medical history, demographics and transthoracic echocardiography (TTE). Participating patients will have their PFO closed using the IrisFITTM PFO Occluder device. The patients will undergo a clinical examination, electrocardiogram (ECG), clinical laboratory assessment and transthoracic echocardiography (TTE). All periprocedural procedures will be performed according to site´s standard of care.. The efficacy and safety of the devices will be assessed by ECGs, vital signs, physical examination and TTE, which will be done at 1day, at 1month and at 6 months post procedure. Safety will also be assessed at 12 months by telephone visit.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients who are according to current international or local guidelines (and future revisions) and per physician discretion scheduled for interventional treatment of PFO.
  • Patients who are willing and capable of providing informed consent and participating in all testing/or follow procedure associated with this study.
  • Patients who are eligible for treatment with IrisFIT PFO occluder device. (Per physician discretion and device IFU).

排除标准

  • PFO tunnel length <1 mm
  • Women of childbearing potential who are or plan to become pregnant during the time of the study (method of assessment upon physician's discretion)
  • Patients who are currently enrolled in another investigational study or registry that would directly interfere with the current study.

结局指标

主要结局

Device related adverse event up to 12 month follow-up

时间窗: 12 month post procedure

Device related adverse event up to 12 month follow-up

Incidence of device migration/malfunction

时间窗: 6 month post procedure

Incidence of device migration/malfunction

Adverse device effects during the procedure up to the point of implanting the study device in the PFO, and during completion of the procedure

时间窗: during completion of the procedure

Adverse device effects during the procedure up to the point of implanting the study device in the PFO, and during completion of the procedure

Device related adverse event up to 1 month follow-up

时间窗: 1 month post procedure

Device related adverse event up to 1 month follow-up

Rate of accurate device placement

时间窗: 6 month post procedure

Rate of accurate device placement

Successful closure/procedure rate: Proper position of the occluder by imaging, with trivial to small or without residual shunt, 6 month after procedure).

时间窗: 6 month post procedure

Successful closure/procedure rate: Proper position of the occluder by imaging, with trivial to small or without residual shunt, 6 month after procedure).

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验